e-Therapeutics plc Notice of AGM and Posting of Annual Report (0085Z)

TIDMETX

RNS Number : 0085Z

e-Therapeutics plc

11 May 2023

e-therapeutics plc

("e-therapeutics" or the "Company")

Notice of Annual General Meeting and Posting of Annual Report and Accounts

London, UK, 11 May 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces that its Annual Report and Accounts for the year ended 31 January 2023, which includes the notice of its 2023 Annual General Meeting ("AGM") have been posted to shareholders today and are available on the Company's website at:

https://www.etherapeutics.co.uk/application/files/9516/8317/9500/ETX_Annual_Report_2023.pdf

The AGM will be held at 12:30p.m. on 18 July 2023 at 4 Kingdom Street, Paddington, London, W2 6BD.

The right to attend and vote at the AGM is determined by reference to the Company's register of members. Only a member entered in the register of members as at close of business on 14 July 2023 (or, if the AGM is adjourned, in the register of members as at the close of business on the date which is two business days before the time of the adjourned AGM) is entitled to attend and vote at the AGM.

Shareholders who wish to register their votes on the resolutions to be put to the AGM should do so by completing and signing the proxy form that accompanies the notice of the AGM (or appoint a proxy electronically if their shares are held in CREST) in accordance with the instructions printed on the proxy form.

Please complete and return the form of proxy in accordance with the instructions printed thereon as soon as possible and, in any event, so that it is received by the Company's registrar, Neville Registrars Limited, Neville House, Steelpark Road, Halesowen, B62 8HD not later than 12:30p.m. on 14 July 2023 .

If you do not have a proxy form and believe that you should have one, or if you have any additional queries on voting, please contact Neville Registrars Limited.

Enquiries:

 
    e-therapeutics plc 
    Ali Mortazavi, CEO                             Tel: +44 (0)20 4551 
     Laura Roca-Alonso, COO/CBO                     8888 
                                                    www.etherapeutics.co.uk 
------------------------------------------------  ------------------------- 
 
     SP Angel Corporate Finance LLP                Tel: +44(0)20 3470 
                                                    0470 
    Nominated Adviser and Broker 
    Matthew Johnson/Harry Davies-Ball (Corporate 
     Finance) 
    Vadim Alexandre/Rob Rees (Corporate Broking) 
------------------------------------------------  -------------------------

About e-therapeutics plc

e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines. The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic.

ETX's proprietary HepNet(TM) platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery. This approach explicitly considers the true complexity of biology to make more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data resource. The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence.

GalOmic (TM) , ETX's proprietary RNAi platform, enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by HepNet(TM) . The focus on hepatocytes offers the opportunity to tackle a wide variety of diseases. The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalOmic (TM) constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.

The Company is progressing a pipeline of first-in-class preclinical RNAi candidates across several high unmet medical needs in cardiometabolic indications and targeting promising hepatocyte-expressed targets with effects in other disease areas. ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.

The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. E-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAAMMFTMTJBBMJ

(END) Dow Jones Newswires

May 11, 2023 02:00 ET (06:00 GMT)

E-therapeutics (LSE:ETX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024